Citations

Clear

951 citation(s) found for "Cohen, M".

Bilateral Ureteral Obstruction Secondary to Retrovesical Hematoma Following Bilateral Ureteral Reimplantation via Cohen Technique
Ellsworth, Pamela , Barraza, Mark A., Stevens, Peter S.

Mayo Clinic

Journal of Urology | January 17, 2006 | Volume: 154 | Issue: 4 | Pages: 1498-1499

10.1016/s0022-5347(01)66913-1 Get It

Workshop Report: Prevention of Postoperative Recurrence in Crohn's Disease
Markowitz, James , Markowitz, Jonathan E. , Bousvaros, Athos, Crandall, Wallace, Faubion, William A. , Kirschner, Barbara S. , Perrault, Jean, Rosh, Joel R. , Winter, Harland S.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | July 28, 2005 | Volume: 41 | Issue: 2 | Pages: 145-151

10.1097/01.mpg.0000172746.86973.ef | PMID 16056092 Get It

Radiation therapy of rectal cancer
Cohen, Alfred M., Gunderson, Leonard L., Welch, Claude E.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 6 | Issue: 5 | Pages: 560-568

10.1007/bf01657870 | PMID 7135986 Get It

AbstractPotentially curative surgery for cancer of the rectum and rectosigmoid is associated with frequent recurrence of the tumor in the pelvis. Data suggest that perioperative radiation therapy can considerably reduce the local failure rate. Pathological risk factors for local recurrence are described. Preoperative and postoperative adjuvant radiation therapy both appear to be effective. Postoperative radiation allows more accurate case selection based on operative findings and pathological staging. Patients with transmural tumor penetration and/or lymph node metastases appear to benefit from adjuvant radiation.
Resident Duty Hours Reform: Results of a National Survey of the Program Directors and Residents in Neurosurgery Training Programs
Cohen‐Gadol, Aaron , Piepgras, David G., Krishnamurthy, Satish , Fessler, Richard D.

Mayo Clinic

Neurosurgery | January 28, 2005 | Volume: 56 | Issue: 2 | Pages: 398-403

10.1227/01.neu.0000147999.64356.57 | PMID 15670388 Get It

Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric Carcinoma
Mansfield, Paul F. , Janjan, Nora A., Morris, Jeffrey S. , Pisters, Peter W. T., Lynch, Patrick M. , Feig, Barry W. , Myerson, Robert J., Nivers, R., Cohen, Deborah S., Gunderson, Leonard L., Ajani, Jaffer A.

Mayo Clinic

Journal of Clinical Oncology | July 14, 2004 | Volume: 22 | Issue: 14 | Pages: 2774-2780

10.1200/jco.2004.01.015 | PMID 15254045 Get It

Purpose In the West, curative (R0) resection is achieved in approximately 50% of patients with localized gastric carcinoma, and more than 60% die of cancer following an R0 resection. A multi-institutional study of preoperative chemoradiotherapy was done to assess the R0 resection rate, pathologic complete response (pathCR) rate, safety, and survival in patients with resectable gastric carcinoma. Patients and Methods Operable patients with localized gastric adenocarcinoma were eligible. Staging also included a laparoscopy and endoscopic ultrasonography (EUS). Patients received up to two 28-day cycles of induction chemotherapy of fluorouracil, leucovorin, and cisplatin, followed by 45 Gy of radiation plus concurrent fluorouracil. Patients were then staged and surgery was attempted. Results Thirty-four patients were registered at three institutions. One ineligible patient was excluded. Most patients had a promixal cancer and EUST3N1 designation. Twenty-eight (85%) of 33 patients underwent surgery. The R0 resection rate was 70% and pathCR rate was 30%. A pathologic partial response (< 10% residual carcinoma in the primary) occurred in eight patients (24%). EUS T plus N and postsurgery T plus N correlation showed significant downstaging (P = < .01). The median survival time for 33 patients was 33.7 months. Patients achieving a pathCR or pathPR had a significantly longer median survival time (63.9 months) than those achieving less than pathPR (12.6 months; P = .03). There were two treatment-related deaths. Conclusion Our data suggest that the three-step strategy of preoperative induction chemotherapy followed by chemoradiotherapy resulted in substantial pathologic response that resulted in durable survival time. This strategy is worthy of a direct comparison with postoperative adjuvant chemoradiotherapy.
Serial Urinary 11-Dehydrothromboxane B2, Aspirin Dose, and Vascular Events in Blacks After Recent Cerebral Infarction
McConnell, Joseph P., Cohen, Stanley N. , Tietjen, Gretchen E. , Wallis, Roi Ann, Gorelick, Philip B. , Bang, Nils U., Bruno, Askiel

Mayo Clinic

Stroke | February 17, 2004 | Volume: 35 | Issue: 3 | Pages: 727-730

10.1161/01.str.0000117097.76953.a6 | PMID 14963281 Get It

Background and Purpose— Incomplete platelet inhibition by aspirin (aspirin resistance) may be a reason for stroke recurrence in some patients. 11-Dehydrothromboxane B2 (11-DTB2) is a stable thromboxane A2 metabolite that reflects in vivo platelet activation. This pilot study was intended to evaluate the reproducibility of urinary 11-DTB2 over time and to look for evidence of aspirin resistance. Methods— All subjects were screened for the African American Antiplatelet Stroke Prevention Study (AAASPS) 7 to 90 days after noncardioembolic cerebral infarction. Of 83 subjects with at least 1 urine sample, 52 were enrolled in AAASPS (randomized to blinded treatment with aspirin 650 mg/d or ticlopidine 500 mg/d), and 31 were enrolled in an open-label antiplatelet therapy cohort. Subjects were followed up for 2 years, with 11-DTB2 measurements scheduled at baseline and 6, 12, and 24 months. Vascular events were cerebral infarction, myocardial infarction, or vascular death. Results— Despite considerable individual up or down fluctuations, the median 11-DTB2 change did not significantly differ from zero in any of the subgroups. However, in 6 subjects with a 4-fold decrease in aspirin dose from 1300 to 325 or 81 mg/d, the 11-DTB2 level increased from 611 to 1881 pg/mg creatinine ( P =0.06). Vascular events occurred in 7 of 61 aspirin-treated subjects, and 11-DTB2 levels did not correlate with the events. Conclusions— Fluctuations in urinary 11-DTB2 after cerebral infarction in blacks do not correlate with changes in aspirin doses, except perhaps when the dose changes by a factor of 4 or more. A larger study is needed to look further for aspirin resistance.
Modeling and Risk Prediction in the Current Era of Interventional Cardiology
Holmes, David R. , Selzer, Faith , Kelsey, Sheryl F., Holubkov, Richard , Cohen, Howard, Williams, David O., Detre, Katherine M., Johnston, Janet M. , Holubkov, Richard

Mayo Clinic

Circulation | April 14, 2003 | Volume: 107 | Issue: 14 | Pages: 1871-1876

10.1161/01.cir.0000065229.72905.78 | PMID 12668511 Get It

Background— Validation of in-hospital mortality models after percutaneous coronary interventions using multicenter data remains limited. Methods and Results— This study evaluated whether multivariable mortality models developed during the pre-stent era by New York State, American College of Cardiology (ACC)–National Cardiovascular Data Registry, Northern New England Cooperative Group, Cleveland Clinic Foundation, and the University of Michigan are relevant in patients undergoing percutaneous coronary intervention in the 1997 to 1999 National Heart, Lung, and Blood Institute Dynamic Registry. Of 4448 Dynamic Registry patients, 73% received ≥1 stent and 28% received a IIB/IIIA receptor inhibitor. In-hospital mortality occurred in 64 patients (1.4%). The New York state model predicted mortality in 69 patients (1.5%; 95% confidence bounds [CI], 0.89% to 1.70%); Northern New England predicted mortality in 60 patients (1.3%; 95% CI, 1.0% to 1.7%); and Cleveland Clinic predicted mortality in 76 patients (1.7%; 95% CI, 1.3% to 2.1%). Among high-risk subgroups, with these 3 models, observed and predicted in-hospital mortality rates in general were not different. The other 2 models yielded different results. The University of Michigan predicted fewer deaths (n=47; 1.1%; 95% CI, 0.7% to 1.3%), and the ACC Registry model predicted 603 deaths (13.5%; 95% CI, 12.6% to 14.4%). Using the ACC Registry model, predicted mortality was higher than observed in each subgroup. Conclusions— Application of 5 mortality risk models developed from different data sets to patients undergoing percutaneous coronary intervention in the Dynamic Registry predicted, in 3 models, mortality rates that were not significantly different than those observed. In both high and low risk subgroups, the University of Michigan slightly underpredicted mortality, and the ACC Registry predicted significantly higher mortality than that observed.
Preoperative Twice-Weekly Paclitaxel With Concurrent Radiation Therapy Followed by Surgery and Postoperative Doxorubicin-Based Chemotherapy in Locally Advanced Breast Cancer: A Phase I/II Trial
Volm, Matthew, Skinner, Kristin A., Spicer, Darcy, Cohen, Deidre, Perez, Edith, Bettini, Anna, Groshen, Susan , Gee, Conway, Florentine, Barbara D., Danenberg, P., Muggia, Franco M. , Formenti, Silvia C. , Press, Michael F.

Mayo Clinic

Journal of Clinical Oncology | February 27, 2003 | Volume: 21 | Issue: 5 | Pages: 864-870

10.1200/jco.2003.06.132 | PMID 12610186 Get It

Purpose: Preoperative chemotherapy is the conventional primary treatment in locally advanced breast cancer (LABC). We investigated the safety and efficacy of primary twice-weekly paclitaxel and concurrent radiation (RT) before modified radical mastectomy followed by adjuvant doxorubicin-based chemotherapy. Patients and Methods: Stage IIB (T3N0) to III LABC patients were eligible. Primary chemoradiation consisted of paclitaxel, 30 mg/m2 delivered intravenously for 1 hour twice weekly for a total of 8 to 10 weeks, and concurrent RT (45 Gy at 1.8 Gy/fraction). Modified radical mastectomy was performed at least 2 weeks after completion of chemoradiation or on recovery of skin toxicity. Postoperatively, patients who responded to paclitaxel and RT received four cycles of doxorubicin/paclitaxel, whereas patients who did not respond received doxorubicin/cytoxan. Results: Forty-four patients were accrued. Toxicity from paclitaxel/RT included grade 3 skin desquamation (7%), hypersensitivity (2%), and stomatitis (2%). Postsurgery complications occurred in six patients (14%). The only grade 4 toxicity of postmastectomy chemotherapy was hematologic (10%). Grade 3 toxicities were leukopenia (24%), infection (22%), peripheral neuropathy (17%), arthralgia and pain (17%), stomatitis (12%), fatigue (10%), esophagitis (5%), and nausea (2%). Overall clinical response rate to preoperative paclitaxel and RT was 91%. Thirty-four percent of patients achieved a pathologic response in the mastectomy specimen: 16% pathologic complete responses (clearance of invasive cancer in the breast and axillary contents) and 18% pathologic partial responses (< 10 residual microscopic foci of invasive breast cancer). Conclusion: Twice-weekly paclitaxel with concurrent RT is a feasible and effective primary treatment for LABC. Future studies should compare primary chemoradiation to chemotherapy in LABC.
Lymphomas in Patients With Connective Tissue Disease
Menke, David M. , Griesser, Henrik, Moder, Kevin G., Tefferi, Ayalew , Luthra, Harvinder S., Cohen, Marc D., Colón‐Otero, Gerardo , Lloyd, Ricardo V.

Mayo Clinic

American Journal of Clinical Pathology | January 8, 2003 | Volume: 113 | Issue: 2 | Pages: 212-218

10.1309/vf28-e64g-1dnd-lf94 | PMID 10664623 Get It

Aspirin and Urinary 11-Dehydrothromboxane B 2 in African American Stroke Patients
McConnell, Joseph P., Mansbach, Harry H., Cohen, Stanley N. , Tietjen, Gretchen E. , Bang, Nils U., Bruno, Askiel

Mayo Clinic

Stroke | July 28, 2002 | Volume: 33 | Issue: 1 | Pages: 57-60

10.1161/hs0102.102010 | PMID 11779889 Get It

Background and Purpose — The aim of the study was to evaluate the relationship between daily aspirin use and urinary excretion of a stable thromboxane metabolite, 11-dehydrothromboxane B 2 (11-DTB2), in African American stroke patients. Methods — Subjects were a subgroup of those screened for the African American Antiplatelet Stroke Prevention Study. Subjects were within 4 months of noncardioembolic ischemic stroke and were not being treated with anticoagulants. Antithrombotic therapy at the time of urine collection varied according to the practice patterns of various attending physicians who treated the patients during their acute strokes. 11-DTB2 was measured by enzyme immunoassay in random urine samples 1 to 4 months after the stroke. Results — Eighty-seven of 92 patients enrolled were able to give a urine sample at the time of enrollment. There were 51 men and 36 women aged 36 to 87 (mean 62) years. On the basis of antithrombotic treatment before the sample collection, we divided patients into 4 groups: (1) 16 patients treated with no aspirin (no antithrombotic drugs [n=4] or ticlopidine [n=12]), (2) 21 patients treated with 81 to 325 mg aspirin per day (81 mg/d [n=2], 325 mg/d [n=19]), (3) 20 patients treated with 650 mg aspirin per day, and (4) 30 patients treated with 975 to 1300 mg aspirin per day (975 mg/d [n=2] and 1300 mg/d [n=28]). In patients taking daily aspirin at any dose, the median urinary 11-DTB2 was 783 pg/mg creatinine compared with 1386 pg/mg creatinine in patients not taking daily aspirin ( P =0.01 by Wilcoxon rank sum test). In multivariate regression analysis, aspirin use remained significantly associated with lower urinary 11-DTB2 ( P =0.008). There was no dose-response effect between the 3 aspirin dose groups and urinary 11-DTB2 ( P =0.70). Conclusions — In African American stroke patients, aspirin use is associated with significantly lower urinary 11-DTB2 independent of other vascular factors, and there does not appear to be a dose-response effect for aspirin doses of 325 to 1300 mg daily. The clinical significance of these finding remains to be determined.